Imago raises $26.5M series A

Myeloid malignancy company Imago BioSciences Inc. (San Francisco, Calif.) raised $26.5 million in a series A round led by Clarus Ventures. Frazier Healthcare; Amgen Ventures; and Merck Research Labs Venture Fund also participated. CEO Hugh Rienhoff did not disclose if the round was tranched, but told BioCentury it was "fully committed."

Imago is focused on therapeutics that alter gene expression. Its lead program is in preclinical development for acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS) and other diseases. ...